UA73265C2 - Adenovirus-recombinant carrying the structure of adenovirus vector, a method for the restoration of protein p53 function in tumor cell with deficit of natural p53, a method for the preparation of adenovirus-recombinant - Google Patents
Adenovirus-recombinant carrying the structure of adenovirus vector, a method for the restoration of protein p53 function in tumor cell with deficit of natural p53, a method for the preparation of adenovirus-recombinant Download PDFInfo
- Publication number
- UA73265C2 UA73265C2 UA96041651A UA96041651A UA73265C2 UA 73265 C2 UA73265 C2 UA 73265C2 UA 96041651 A UA96041651 A UA 96041651A UA 96041651 A UA96041651 A UA 96041651A UA 73265 C2 UA73265 C2 UA 73265C2
- Authority
- UA
- Ukraine
- Prior art keywords
- adenovirus
- fact
- cells
- recombinant
- cell
- Prior art date
Links
- 241000701161 unidentified adenovirus Species 0.000 title claims abstract description 146
- 238000000034 method Methods 0.000 title claims abstract description 131
- 239000013598 vector Substances 0.000 title claims description 52
- 238000002360 preparation method Methods 0.000 title claims description 12
- 210000004881 tumor cell Anatomy 0.000 title claims description 11
- 230000006735 deficit Effects 0.000 title 1
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 150
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 45
- 230000010076 replication Effects 0.000 claims abstract description 22
- 210000004027 cell Anatomy 0.000 claims description 322
- 206010028980 Neoplasm Diseases 0.000 claims description 110
- 230000014509 gene expression Effects 0.000 claims description 91
- 241000700605 Viruses Species 0.000 claims description 80
- 201000011510 cancer Diseases 0.000 claims description 59
- 238000011282 treatment Methods 0.000 claims description 56
- 101000721661 Homo sapiens Cellular tumor antigen p53 Proteins 0.000 claims description 49
- 208000020816 lung neoplasm Diseases 0.000 claims description 42
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 41
- 201000005202 lung cancer Diseases 0.000 claims description 41
- 238000001890 transfection Methods 0.000 claims description 41
- 238000006243 chemical reaction Methods 0.000 claims description 37
- 230000000120 cytopathologic effect Effects 0.000 claims description 32
- 230000012010 growth Effects 0.000 claims description 32
- 238000006116 polymerization reaction Methods 0.000 claims description 28
- 230000003612 virological effect Effects 0.000 claims description 28
- 230000035772 mutation Effects 0.000 claims description 23
- 241000701022 Cytomegalovirus Species 0.000 claims description 19
- 239000013612 plasmid Substances 0.000 claims description 17
- 230000010261 cell growth Effects 0.000 claims description 16
- 230000008488 polyadenylation Effects 0.000 claims description 14
- 238000004458 analytical method Methods 0.000 claims description 13
- 239000013604 expression vector Substances 0.000 claims description 12
- 238000004519 manufacturing process Methods 0.000 claims description 12
- 239000003814 drug Substances 0.000 claims description 10
- 230000003211 malignant effect Effects 0.000 claims description 10
- 238000011161 development Methods 0.000 claims description 9
- 239000002502 liposome Substances 0.000 claims description 9
- 238000002347 injection Methods 0.000 claims description 8
- 239000007924 injection Substances 0.000 claims description 8
- 239000000203 mixture Substances 0.000 claims description 8
- 108700025694 p53 Genes Proteins 0.000 claims description 8
- 230000001629 suppression Effects 0.000 claims description 8
- 241001465754 Metazoa Species 0.000 claims description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 7
- 102000007469 Actins Human genes 0.000 claims description 6
- 108010085238 Actins Proteins 0.000 claims description 6
- 206010006187 Breast cancer Diseases 0.000 claims description 6
- 208000026310 Breast neoplasm Diseases 0.000 claims description 6
- 230000007547 defect Effects 0.000 claims description 6
- 201000010099 disease Diseases 0.000 claims description 6
- 239000006228 supernatant Substances 0.000 claims description 6
- 241000220317 Rosa Species 0.000 claims description 5
- 230000007812 deficiency Effects 0.000 claims description 4
- 210000005260 human cell Anatomy 0.000 claims description 4
- 210000004962 mammalian cell Anatomy 0.000 claims description 4
- 230000001394 metastastic effect Effects 0.000 claims description 4
- 206010061289 metastatic neoplasm Diseases 0.000 claims description 4
- 201000009030 Carcinoma Diseases 0.000 claims description 3
- 206010027476 Metastases Diseases 0.000 claims description 3
- 230000001747 exhibiting effect Effects 0.000 claims description 3
- 238000010253 intravenous injection Methods 0.000 claims description 3
- 230000006798 recombination Effects 0.000 claims description 3
- 238000005215 recombination Methods 0.000 claims description 3
- 102000010292 Peptide Elongation Factor 1 Human genes 0.000 claims description 2
- 108010077524 Peptide Elongation Factor 1 Proteins 0.000 claims description 2
- 108010007568 Protamines Proteins 0.000 claims description 2
- 238000001802 infusion Methods 0.000 claims description 2
- 229940079593 drug Drugs 0.000 claims 8
- 241000124008 Mammalia Species 0.000 claims 5
- 102000007327 Protamines Human genes 0.000 claims 1
- 210000004102 animal cell Anatomy 0.000 claims 1
- 230000006907 apoptotic process Effects 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 229940048914 protamine Drugs 0.000 claims 1
- 238000012876 topography Methods 0.000 claims 1
- 238000012546 transfer Methods 0.000 abstract description 25
- 230000002950 deficient Effects 0.000 abstract description 9
- 230000001225 therapeutic effect Effects 0.000 abstract description 9
- 230000001404 mediated effect Effects 0.000 abstract description 3
- 210000001035 gastrointestinal tract Anatomy 0.000 abstract 2
- 230000009885 systemic effect Effects 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 description 46
- 230000008569 process Effects 0.000 description 31
- 239000000047 product Substances 0.000 description 21
- 230000015572 biosynthetic process Effects 0.000 description 20
- 230000006870 function Effects 0.000 description 20
- 210000002845 virion Anatomy 0.000 description 20
- 238000005755 formation reaction Methods 0.000 description 18
- 108700020796 Oncogene Proteins 0.000 description 16
- 230000000694 effects Effects 0.000 description 16
- 210000003205 muscle Anatomy 0.000 description 16
- 102000043276 Oncogene Human genes 0.000 description 14
- 238000001415 gene therapy Methods 0.000 description 14
- 239000002609 medium Substances 0.000 description 12
- 241000699670 Mus sp. Species 0.000 description 11
- 229910000389 calcium phosphate Inorganic materials 0.000 description 10
- 239000001506 calcium phosphate Substances 0.000 description 10
- 235000011010 calcium phosphates Nutrition 0.000 description 10
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 10
- 210000005056 cell body Anatomy 0.000 description 9
- 239000000523 sample Substances 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- 238000004113 cell culture Methods 0.000 description 8
- 238000011160 research Methods 0.000 description 8
- 210000001519 tissue Anatomy 0.000 description 8
- 230000003321 amplification Effects 0.000 description 7
- 239000012634 fragment Substances 0.000 description 7
- 210000004072 lung Anatomy 0.000 description 7
- 238000003199 nucleic acid amplification method Methods 0.000 description 7
- 108020004707 nucleic acids Proteins 0.000 description 7
- 150000007523 nucleic acids Chemical class 0.000 description 7
- 102000039446 nucleic acids Human genes 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- 238000002560 therapeutic procedure Methods 0.000 description 7
- 108020004414 DNA Proteins 0.000 description 6
- 241000701024 Human betaherpesvirus 5 Species 0.000 description 6
- 239000007853 buffer solution Substances 0.000 description 6
- 230000007423 decrease Effects 0.000 description 6
- 238000012217 deletion Methods 0.000 description 6
- 230000037430 deletion Effects 0.000 description 6
- 239000000499 gel Substances 0.000 description 6
- 238000011081 inoculation Methods 0.000 description 6
- 230000009466 transformation Effects 0.000 description 6
- 108700025695 Suppressor Genes Proteins 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 230000001276 controlling effect Effects 0.000 description 5
- 238000005516 engineering process Methods 0.000 description 5
- 230000002068 genetic effect Effects 0.000 description 5
- 210000001370 mediastinum Anatomy 0.000 description 5
- 230000001177 retroviral effect Effects 0.000 description 5
- 238000003786 synthesis reaction Methods 0.000 description 5
- 238000013518 transcription Methods 0.000 description 5
- 230000035897 transcription Effects 0.000 description 5
- 241001430294 unidentified retrovirus Species 0.000 description 5
- 229920000936 Agarose Polymers 0.000 description 4
- 229920000742 Cotton Polymers 0.000 description 4
- 241001135569 Human adenovirus 5 Species 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- 230000001413 cellular effect Effects 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 230000001965 increasing effect Effects 0.000 description 4
- 239000010410 layer Substances 0.000 description 4
- 239000003550 marker Substances 0.000 description 4
- 230000001766 physiological effect Effects 0.000 description 4
- 238000012545 processing Methods 0.000 description 4
- 230000001105 regulatory effect Effects 0.000 description 4
- 238000010186 staining Methods 0.000 description 4
- 238000006467 substitution reaction Methods 0.000 description 4
- 108020004705 Codon Proteins 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 206010053759 Growth retardation Diseases 0.000 description 3
- 101000686031 Homo sapiens Proto-oncogene tyrosine-protein kinase ROS Proteins 0.000 description 3
- 241000598171 Human adenovirus sp. Species 0.000 description 3
- 239000005089 Luciferase Substances 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 108010089430 Phosphoproteins Proteins 0.000 description 3
- 102000007982 Phosphoproteins Human genes 0.000 description 3
- 108700020978 Proto-Oncogene Proteins 0.000 description 3
- 102000052575 Proto-Oncogene Human genes 0.000 description 3
- 206010039491 Sarcoma Diseases 0.000 description 3
- 108700025716 Tumor Suppressor Genes Proteins 0.000 description 3
- 102000044209 Tumor Suppressor Genes Human genes 0.000 description 3
- 238000001574 biopsy Methods 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 210000000349 chromosome Anatomy 0.000 description 3
- 238000012790 confirmation Methods 0.000 description 3
- 239000012228 culture supernatant Substances 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 230000007850 degeneration Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 230000006801 homologous recombination Effects 0.000 description 3
- 238000002744 homologous recombination Methods 0.000 description 3
- 230000002055 immunohistochemical effect Effects 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 230000033001 locomotion Effects 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 235000015097 nutrients Nutrition 0.000 description 3
- 231100000590 oncogenic Toxicity 0.000 description 3
- 230000002246 oncogenic effect Effects 0.000 description 3
- 238000011275 oncology therapy Methods 0.000 description 3
- 238000004806 packaging method and process Methods 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 238000001556 precipitation Methods 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 238000001959 radiotherapy Methods 0.000 description 3
- 238000000844 transformation Methods 0.000 description 3
- 230000005740 tumor formation Effects 0.000 description 3
- 230000004614 tumor growth Effects 0.000 description 3
- 230000017613 viral reproduction Effects 0.000 description 3
- 208000010370 Adenoviridae Infections Diseases 0.000 description 2
- 206010060931 Adenovirus infection Diseases 0.000 description 2
- 239000002028 Biomass Substances 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 108091026890 Coding region Proteins 0.000 description 2
- 108010067770 Endopeptidase K Proteins 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 244000068988 Glycine max Species 0.000 description 2
- 235000010469 Glycine max Nutrition 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 2
- 208000026350 Inborn Genetic disease Diseases 0.000 description 2
- 241001529936 Murinae Species 0.000 description 2
- 241000282376 Panthera tigris Species 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 108700025701 Retinoblastoma Genes Proteins 0.000 description 2
- 241000700584 Simplexvirus Species 0.000 description 2
- 108700005077 Viral Genes Proteins 0.000 description 2
- 108010067390 Viral Proteins Proteins 0.000 description 2
- 208000036142 Viral infection Diseases 0.000 description 2
- 208000011589 adenoviridae infectious disease Diseases 0.000 description 2
- 239000011543 agarose gel Substances 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 238000013276 bronchoscopy Methods 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- AIYUHDOJVYHVIT-UHFFFAOYSA-M caesium chloride Chemical compound [Cl-].[Cs+] AIYUHDOJVYHVIT-UHFFFAOYSA-M 0.000 description 2
- 230000000711 cancerogenic effect Effects 0.000 description 2
- 231100000315 carcinogenic Toxicity 0.000 description 2
- 239000006143 cell culture medium Substances 0.000 description 2
- 230000022131 cell cycle Effects 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 238000012937 correction Methods 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- 101150061286 dabB gene Proteins 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 208000016361 genetic disease Diseases 0.000 description 2
- 230000009036 growth inhibition Effects 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000002458 infectious effect Effects 0.000 description 2
- 238000009434 installation Methods 0.000 description 2
- 230000010354 integration Effects 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 208000037841 lung tumor Diseases 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- RFKMCNOHBTXSMU-UHFFFAOYSA-N methoxyflurane Chemical compound COC(F)(F)C(Cl)Cl RFKMCNOHBTXSMU-UHFFFAOYSA-N 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 238000002703 mutagenesis Methods 0.000 description 2
- 231100000350 mutagenesis Toxicity 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 230000001613 neoplastic effect Effects 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 238000003752 polymerase chain reaction Methods 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 230000003362 replicative effect Effects 0.000 description 2
- 210000002345 respiratory system Anatomy 0.000 description 2
- 239000013049 sediment Substances 0.000 description 2
- 230000000391 smoking effect Effects 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 230000001131 transforming effect Effects 0.000 description 2
- 239000002753 trypsin inhibitor Substances 0.000 description 2
- 230000009385 viral infection Effects 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 101150094765 70 gene Proteins 0.000 description 1
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical group CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- 108010087905 Adenovirus E1B Proteins Proteins 0.000 description 1
- 108700028369 Alleles Proteins 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 240000002791 Brassica napus Species 0.000 description 1
- 235000004977 Brassica sinapistrum Nutrition 0.000 description 1
- 206010006542 Bulbar palsy Diseases 0.000 description 1
- 210000003771 C cell Anatomy 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 206010057248 Cell death Diseases 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 206010011409 Cross infection Diseases 0.000 description 1
- 241000450599 DNA viruses Species 0.000 description 1
- 206010012239 Delusion Diseases 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000020897 Formins Human genes 0.000 description 1
- 108091022623 Formins Proteins 0.000 description 1
- 108090000144 Human Proteins Proteins 0.000 description 1
- 102000003839 Human Proteins Human genes 0.000 description 1
- 241000701109 Human adenovirus 2 Species 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 101150037050 LE gene Proteins 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 108060001084 Luciferase Proteins 0.000 description 1
- 241000829100 Macaca mulatta polyomavirus 1 Species 0.000 description 1
- 206010064912 Malignant transformation Diseases 0.000 description 1
- 102000048850 Neoplasm Genes Human genes 0.000 description 1
- 108700019961 Neoplasm Genes Proteins 0.000 description 1
- 244000004005 Nypa fruticans Species 0.000 description 1
- 235000005305 Nypa fruticans Nutrition 0.000 description 1
- XDMCWZFLLGVIID-SXPRBRBTSA-N O-(3-O-D-galactosyl-N-acetyl-beta-D-galactosaminyl)-L-serine Chemical compound CC(=O)N[C@H]1[C@H](OC[C@H]([NH3+])C([O-])=O)O[C@H](CO)[C@H](O)[C@@H]1OC1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 XDMCWZFLLGVIID-SXPRBRBTSA-N 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 208000000474 Poliomyelitis Diseases 0.000 description 1
- 108700005075 Regulator Genes Proteins 0.000 description 1
- 201000000582 Retinoblastoma Diseases 0.000 description 1
- 241000144282 Sigmodon Species 0.000 description 1
- 244000111306 Torreya nucifera Species 0.000 description 1
- 235000006732 Torreya nucifera Nutrition 0.000 description 1
- 108700019146 Transgenes Proteins 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 108010040002 Tumor Suppressor Proteins Proteins 0.000 description 1
- 102000001742 Tumor Suppressor Proteins Human genes 0.000 description 1
- 108070000030 Viral receptors Proteins 0.000 description 1
- 101150003160 X gene Proteins 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000004308 accommodation Effects 0.000 description 1
- 230000035508 accumulation Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 208000009956 adenocarcinoma Diseases 0.000 description 1
- 208000030961 allergic reaction Diseases 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 238000011888 autopsy Methods 0.000 description 1
- 230000037429 base substitution Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 230000007321 biological mechanism Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 238000002725 brachytherapy Methods 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 208000035269 cancer or benign tumor Diseases 0.000 description 1
- 210000000234 capsid Anatomy 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 235000019994 cava Nutrition 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 239000013553 cell monolayer Substances 0.000 description 1
- 230000007248 cellular mechanism Effects 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- YTRQFSDWAXHJCC-UHFFFAOYSA-N chloroform;phenol Chemical compound ClC(Cl)Cl.OC1=CC=CC=C1 YTRQFSDWAXHJCC-UHFFFAOYSA-N 0.000 description 1
- 230000002759 chromosomal effect Effects 0.000 description 1
- 235000019504 cigarettes Nutrition 0.000 description 1
- 238000000975 co-precipitation Methods 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 231100000517 death Toxicity 0.000 description 1
- 238000005202 decontamination Methods 0.000 description 1
- 230000003588 decontaminative effect Effects 0.000 description 1
- 231100000868 delusion Toxicity 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 230000005584 early death Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 229940096118 ella Drugs 0.000 description 1
- 238000001839 endoscopy Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 230000003631 expected effect Effects 0.000 description 1
- 230000004438 eyesight Effects 0.000 description 1
- 108010074605 gamma-Globulins Proteins 0.000 description 1
- 238000001476 gene delivery Methods 0.000 description 1
- 238000012637 gene transfection Methods 0.000 description 1
- 238000002695 general anesthesia Methods 0.000 description 1
- 230000009395 genetic defect Effects 0.000 description 1
- 210000004602 germ cell Anatomy 0.000 description 1
- 230000007773 growth pattern Effects 0.000 description 1
- 239000003630 growth substance Substances 0.000 description 1
- 150000003278 haem Chemical class 0.000 description 1
- 230000009931 harmful effect Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 238000002991 immunohistochemical analysis Methods 0.000 description 1
- 238000012744 immunostaining Methods 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000005865 ionizing radiation Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 238000002690 local anesthesia Methods 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 230000002934 lysing effect Effects 0.000 description 1
- 230000002101 lytic effect Effects 0.000 description 1
- 230000036212 malign transformation Effects 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 229940126601 medicinal product Drugs 0.000 description 1
- 210000002783 mesonephros Anatomy 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 210000000663 muscle cell Anatomy 0.000 description 1
- 230000000955 neuroendocrine Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- KDYILQLPKVZDGB-UHFFFAOYSA-N octadeca-9,12-diynoic acid Chemical compound CCCCCC#CCC#CCCCCCCCC(O)=O KDYILQLPKVZDGB-UHFFFAOYSA-N 0.000 description 1
- 108091008819 oncoproteins Proteins 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000008196 pharmacological composition Substances 0.000 description 1
- 238000002135 phase contrast microscopy Methods 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 230000006659 positive regulation of apoptotic process Effects 0.000 description 1
- 231100000683 possible toxicity Toxicity 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 201000002241 progressive bulbar palsy Diseases 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 239000011435 rock Substances 0.000 description 1
- 239000003566 sealing material Substances 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 238000002633 shock therapy Methods 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 239000000779 smoke Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 206010041823 squamous cell carcinoma Diseases 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 238000004114 suspension culture Methods 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 102000003390 tumor necrosis factor Human genes 0.000 description 1
- 230000005760 tumorsuppression Effects 0.000 description 1
- OOLLAFOLCSJHRE-ZHAKMVSLSA-N ulipristal acetate Chemical compound C1=CC(N(C)C)=CC=C1[C@@H]1C2=C3CCC(=O)C=C3CC[C@H]2[C@H](CC[C@]2(OC(C)=O)C(C)=O)[C@]2(C)C1 OOLLAFOLCSJHRE-ZHAKMVSLSA-N 0.000 description 1
- 230000004222 uncontrolled growth Effects 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 230000002477 vacuolizing effect Effects 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 230000029812 viral genome replication Effects 0.000 description 1
- 210000000605 viral structure Anatomy 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4746—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used p53
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Virology (AREA)
- Immunology (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Physics & Mathematics (AREA)
- Gastroenterology & Hepatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Plant Pathology (AREA)
- Epidemiology (AREA)
- Marine Sciences & Fisheries (AREA)
- Toxicology (AREA)
- Oncology (AREA)
- Analytical Chemistry (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/145,826 US6410010B1 (en) | 1992-10-13 | 1993-10-29 | Recombinant P53 adenovirus compositions |
| PCT/US1994/012401 WO1995012660A2 (en) | 1993-10-29 | 1994-10-28 | Recombinant p53 adenovirus methods and compositions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UA73265C2 true UA73265C2 (en) | 2005-07-15 |
Family
ID=22514730
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UA96041651A UA73265C2 (en) | 1993-10-29 | 1994-10-28 | Adenovirus-recombinant carrying the structure of adenovirus vector, a method for the restoration of protein p53 function in tumor cell with deficit of natural p53, a method for the preparation of adenovirus-recombinant |
Country Status (18)
| Country | Link |
|---|---|
| US (9) | US6410010B1 (de) |
| EP (1) | EP0725791B1 (de) |
| JP (2) | JPH10503361A (de) |
| KR (2) | KR100812631B1 (de) |
| CN (1) | CN1079833C (de) |
| AT (1) | ATE525387T1 (de) |
| AU (1) | AU698437B2 (de) |
| BR (1) | BR9408179A (de) |
| CA (1) | CA2174556C (de) |
| CZ (1) | CZ288790B6 (de) |
| HU (1) | HU222981B1 (de) |
| NO (1) | NO961696L (de) |
| NZ (1) | NZ275356A (de) |
| PL (1) | PL186151B1 (de) |
| RU (1) | RU2222600C2 (de) |
| SK (1) | SK50996A3 (de) |
| UA (1) | UA73265C2 (de) |
| WO (1) | WO1995012660A2 (de) |
Families Citing this family (112)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6605712B1 (en) * | 1990-12-20 | 2003-08-12 | Arch Development Corporation | Gene transcription and ionizing radiation: methods and compositions |
| EP0575518A1 (de) * | 1991-03-06 | 1993-12-29 | Board Of Regents, The University Of Texas System | Verfahren und zusammensetzungen fuer die selektive hemmung von genexpression |
| US5747469A (en) * | 1991-03-06 | 1998-05-05 | Board Of Regents, The University Of Texas System | Methods and compositions comprising DNA damaging agents and p53 |
| US6410010B1 (en) * | 1992-10-13 | 2002-06-25 | Board Of Regents, The University Of Texas System | Recombinant P53 adenovirus compositions |
| US6210939B1 (en) * | 1993-10-25 | 2001-04-03 | Canji, Inc. | Recombinant adenoviral vector and methods of use |
| PT797676E (pt) * | 1993-10-25 | 2006-05-31 | Canji Inc | Vector adenoviral recombinante e metodos de utilizacao |
| US20060275261A1 (en) * | 1993-10-25 | 2006-12-07 | Canji, Inc. | Adenoviral vectors having a protein IX deletion |
| US20070259429A9 (en) * | 1993-10-25 | 2007-11-08 | Canji,Inc. | Adenoviral vectors having a protein IX deletion |
| US20010006629A1 (en) * | 1993-10-25 | 2001-07-05 | Richard J. Gregory | Recombinant adenoviral vector and methods of use |
| US20020010144A1 (en) * | 1994-04-29 | 2002-01-24 | Robert Sobol | Enhancing the sensitivity of tumor cells to therapies |
| US7592317B1 (en) * | 1994-08-11 | 2009-09-22 | The University Of Chicago | Constitutive gene expression in conjuction with ionizing radiation |
| US6638762B1 (en) | 1994-11-28 | 2003-10-28 | Genetic Therapy, Inc. | Tissue-vectors specific replication and gene expression |
| CA2206205A1 (en) * | 1994-11-28 | 1996-06-06 | Genetic Therapy, Inc. | Tissue-specific treatment, diagnostic methods, and compositions using replication-deficient vectors |
| US5998205A (en) * | 1994-11-28 | 1999-12-07 | Genetic Therapy, Inc. | Vectors for tissue-specific replication |
| FR2729295A1 (fr) * | 1995-01-17 | 1996-07-19 | Rhone Poulenc Rorer Sa | Traitement therapeutique combine des pathologies hyperproliferatives |
| AU5297496A (en) * | 1995-02-17 | 1996-09-04 | Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The | Methods of preparation and use of recombinant adenoviral vectors |
| AU722042B2 (en) * | 1995-11-30 | 2000-07-20 | Board Of Regents, The University Of Texas System | Methods and compositions for the diagnosis and treatment of cancer |
| EP1724350A1 (de) * | 1995-11-30 | 2006-11-22 | The Board Of Regents, The University Of Texas System | Verfahren und Zusammensetzungen zur Diagnose und Behandlung von Krebs |
| US6133243A (en) * | 1996-02-22 | 2000-10-17 | Onyx Pharmaceuticals, Inc. | Liposomal-viral DNA complexes for treating disease |
| US5958892A (en) * | 1996-07-30 | 1999-09-28 | Board Of Regents, The University Of Texas System | 2-methoxyestradiol-induced apoptosis in cancer cells |
| AU4328897A (en) * | 1996-08-23 | 1998-03-06 | Board Of Regents, The University Of Texas System | Anti-proliferative factor from transfected cells |
| JP2001505766A (ja) * | 1996-11-18 | 2001-05-08 | マクギル ユニバーシティー | アポトーシスと生長を調節するアデノウイルスベクターを有する、有糸分裂後のニューロン |
| ATE550429T1 (de) * | 1996-11-20 | 2012-04-15 | Crucell Holland Bv | Adenovirus-zusammensetzungen erhältlich durch ein verbessertes produktions- und reinigungsverfahren |
| US7732129B1 (en) * | 1998-12-01 | 2010-06-08 | Crucell Holland B.V. | Method for the production and purification of adenoviral vectors |
| BR9808697A (pt) * | 1997-04-28 | 2000-07-11 | Rhone Poulenc Rorer Sa | Processo para inibir o crescimento de um tumor, vetor de adenovìrus defeituoso, vetor de vìrus, uso do mesmo, e, composição farmacêutica |
| US20050096288A1 (en) * | 1997-06-13 | 2005-05-05 | Aragene, Inc. | Lipoproteins as nucleic acid vectors |
| US6635623B1 (en) * | 1997-06-13 | 2003-10-21 | Baylor College Of Medicine | Lipoproteins as nucleic acid vectors |
| US6689600B1 (en) | 1998-11-16 | 2004-02-10 | Introgen Therapeutics, Inc. | Formulation of adenovirus for gene therapy |
| US20050063950A1 (en) * | 1998-11-19 | 2005-03-24 | Georgetown University | Systemic viral/ligand gene delivery system and gene therapy |
| US20020086840A1 (en) * | 2000-01-26 | 2002-07-04 | Zarling David A. | Use of Rad51 inhibitors for p53 gene therapy |
| ES2380007T3 (es) * | 2001-04-06 | 2012-05-07 | The University Of Chicago | Inducción por agentes quimioterapéuticos de la actividad del promotor Egr-1 en la terapia génica |
| US8034791B2 (en) | 2001-04-06 | 2011-10-11 | The University Of Chicago | Activation of Egr-1 promoter by DNA damaging chemotherapeutics |
| US20040242523A1 (en) * | 2003-03-06 | 2004-12-02 | Ana-Farber Cancer Institue And The Univiersity Of Chicago | Chemo-inducible cancer gene therapy |
| KR100432953B1 (ko) * | 2001-09-01 | 2004-05-28 | 김주항 | 개선된 종양 살상 효과를 나타내는 재조합 아데노바이러스 |
| EP1327688A1 (de) * | 2002-01-14 | 2003-07-16 | Vereniging Voor Christelijk Wetenschappelijk Onderwijs | Adenoviren mit erhöhter Lysisfähigkeit |
| US7078037B2 (en) * | 2002-04-19 | 2006-07-18 | The Arizona Board Of Regents On Behalf Of The University Of Arizona | Peptides and DNA encoding the peptides useful for immunizations against Coccidioides spp. infections |
| CA2511625A1 (en) * | 2002-12-23 | 2004-07-15 | City Of Hope | Modified vaccinia ankara expressing p53 in cancer immunotherapy |
| CA2518169C (en) * | 2003-03-06 | 2012-01-24 | Zhaohui Peng | A recombinant constructed by a virus vector and a human tumor suppressor gene and its use |
| US7262027B2 (en) * | 2003-03-14 | 2007-08-28 | Medical College Of Ohio | Polypeptide and DNA immunization against Coccidioides spp. infections |
| US20080039409A1 (en) * | 2003-12-24 | 2008-02-14 | Locomogene, Inc. | Method of Suppressing Cancer |
| JPWO2005061007A1 (ja) * | 2003-12-24 | 2007-07-12 | 学校法人 聖マリアンナ医科大学 | 癌の抑制方法 |
| WO2005082422A1 (en) * | 2004-02-24 | 2005-09-09 | Introgen Therapeutics, Inc. | Combination of ad-p53 and chemotherapy for the treatment of tumours |
| US20070212298A1 (en) * | 2004-08-25 | 2007-09-13 | Prefix Suffix | Use of the combination comprising temozolomide and tnf-alpha for treating glioblastoma |
| US8926987B2 (en) | 2004-11-18 | 2015-01-06 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Replication-competent adenoviral vectors |
| CA2595874A1 (en) * | 2005-01-26 | 2006-08-03 | Zhaohui Peng | The new use of recombinant adenovirus-p53 agent in treatment of tumor patients |
| JO2660B1 (en) | 2006-01-20 | 2012-06-17 | نوفارتيس ايه جي | Pi-3 inhibitors and methods of use |
| US20070231304A1 (en) * | 2006-01-30 | 2007-10-04 | Introgen Therapeutics, Inc. | Prognostic factors for anti-hyperproliferative disease gene therapy |
| TW200808739A (en) | 2006-04-06 | 2008-02-16 | Novartis Vaccines & Diagnostic | Quinazolines for PDK1 inhibition |
| US20080027016A1 (en) * | 2006-07-28 | 2008-01-31 | Nicholas Anthony Laszlo | Cancer treatment application of genomic replacement therapy |
| PA8809001A1 (es) | 2007-12-20 | 2009-07-23 | Novartis Ag | Compuestos organicos |
| JP5674476B2 (ja) | 2008-01-25 | 2015-02-25 | ピー５３ インコーポレイテッド | Ｐ５３バイオマーカー |
| US9050276B2 (en) | 2009-06-16 | 2015-06-09 | The Trustees Of Columbia University In The City Of New York | Autism-associated biomarkers and uses thereof |
| US8293753B2 (en) | 2009-07-02 | 2012-10-23 | Novartis Ag | Substituted 2-carboxamide cycloamino ureas |
| BR112012019635A2 (pt) | 2010-02-22 | 2016-05-03 | Hoffmann La Roche | compostos inibidores de pirido[3,2-d] pirimidina pi3k delta e métodos de uso |
| AR082418A1 (es) | 2010-08-02 | 2012-12-05 | Novartis Ag | Formas cristalinas de 1-(4-metil-5-[2-(2,2,2-trifluoro-1,1-dimetil-etil)-piridin-4-il]-tiazol-2-il)-amida de 2-amida del acido (s)-pirrolidin-1,2-dicarboxilico |
| BR112013009196A2 (pt) | 2010-10-15 | 2020-08-25 | The Trustees Of Columbia University In The City Of New York | usos de polipeptídeo para redução da aquisição de ácido graxo e da ingestão de alimento, bem como para promoção de saciedade relacionados à obesidade |
| WO2012061537A2 (en) | 2010-11-02 | 2012-05-10 | The Trustees Of Columbia University In The City Of New York | Methods for treating hair loss disorders |
| KR101928116B1 (ko) | 2011-01-31 | 2018-12-11 | 노파르티스 아게 | 신규 헤테로시클릭 유도체 |
| BR112013020875A2 (pt) | 2011-02-15 | 2019-09-24 | Immune Design Corp | método para indução de uma resposta imune específica para um imunógeno em um indivíduo. |
| AU2012243039B2 (en) | 2011-04-08 | 2017-07-13 | Immune Design Corp. | Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses |
| US20130189754A1 (en) | 2011-09-12 | 2013-07-25 | International Aids Vaccine Initiative | Immunoselection of recombinant vesicular stomatitis virus expressing hiv-1 proteins by broadly neutralizing antibodies |
| EP2586461A1 (de) | 2011-10-27 | 2013-05-01 | Christopher L. Parks | Von einem eingehüllten Virus abgeleitete Virenpartikel |
| CA2853256C (en) | 2011-10-28 | 2019-05-14 | Novartis Ag | Novel purine derivatives and their use in the treatment of disease |
| US10039777B2 (en) | 2012-03-20 | 2018-08-07 | Neuro-Lm Sas | Methods and pharmaceutical compositions of the treatment of autistic syndrome disorders |
| PL2830662T3 (pl) | 2012-03-29 | 2019-02-28 | The Trustees Of Columbia University In The City Of New York | Sposoby leczenia zaburzeń utraty włosów |
| US9347065B2 (en) | 2012-03-29 | 2016-05-24 | International Aids Vaccine Initiative | Methods to improve vector expression and genetic stability |
| WO2013152230A1 (en) | 2012-04-04 | 2013-10-10 | The Trustees Of Columbia University In The City Of New York | Smooth muscle specific inhibition for anti-restenotic therapy |
| RS57420B1 (sr) | 2012-05-16 | 2018-09-28 | Immune Design Corp | Vakcine za hsv-2 |
| SG11201406550QA (en) | 2012-05-16 | 2014-11-27 | Novartis Ag | Dosage regimen for a pi-3 kinase inhibitor |
| AU2014236207B2 (en) | 2013-03-14 | 2019-05-23 | Salk Institute For Biological Studies | Oncolytic adenovirus compositions |
| AU2014236947A1 (en) | 2013-03-15 | 2015-09-03 | The Trustees Of Columbia University In The City Of New York | Fusion proteins and methods thereof |
| KR20160095035A (ko) | 2013-12-06 | 2016-08-10 | 노파르티스 아게 | 알파-이소형 선택성 포스파티딜이노시톨 3-키나제 억제제를 위한 투여 요법 |
| US9682123B2 (en) | 2013-12-20 | 2017-06-20 | The Trustees Of Columbia University In The City Of New York | Methods of treating metabolic disease |
| EP3104878B1 (de) | 2014-02-14 | 2019-05-22 | Immune Design Corp. | Immuntherapie von krebs durch kombination von lokaler und systemischer immunstimulation |
| WO2016011083A1 (en) | 2014-07-15 | 2016-01-21 | Immune Design Corp. | Prime-boost regimens with a tlr4 agonist adjuvant and a lentiviral vector |
| WO2016105517A1 (en) | 2014-12-23 | 2016-06-30 | The Trustees Of Columbia University In The City Of New York | Fusion proteins and methods thereof |
| CA2997947A1 (en) | 2015-09-09 | 2017-03-16 | The Trustees Of Columbia University In The City Of New York | Reduction of er-mam-localized app-c99 and methods of treating alzheimer's disease |
| US10188750B1 (en) | 2015-10-23 | 2019-01-29 | University Of South Florida | Self-replicating cell selective gene delivery compositions, methods, and uses thereof |
| LT3370733T (lt) | 2015-11-02 | 2021-10-25 | Board Of Regents, The University Of Texas System | Cd40 aktyvinimo ir imuninės kontrolės taškų blokados būdai |
| CA3002954A1 (en) | 2015-11-02 | 2017-05-11 | Novartis Ag | Dosage regimen for a phosphatidylinositol 3-kinase inhibitor |
| US20190038713A1 (en) | 2015-11-07 | 2019-02-07 | Multivir Inc. | Compositions comprising tumor suppressor gene therapy and immune checkpoint blockade for the treatment of cancer |
| WO2017147265A1 (en) | 2016-02-23 | 2017-08-31 | Salk Institute For Biological Studies | High throughput assay for measuring adenovirus replication kinetics |
| CA3013639A1 (en) | 2016-02-23 | 2017-08-31 | Salk Institute For Biological Studies | Exogenous gene expression in therapeutic adenovirus for minimal impact on viral kinetics |
| KR20230051602A (ko) | 2016-04-15 | 2023-04-18 | 알파인 이뮨 사이언시즈, 인코포레이티드 | Icos 리간드 변이체 면역조절 단백질 및 그의 용도 |
| NZ746934A (en) | 2016-04-15 | 2023-11-24 | Alpine Immune Sciences Inc | Cd80 variant immunomodulatory proteins and uses thereof |
| JP7099967B2 (ja) | 2016-07-01 | 2022-07-12 | リサーチ ディベロップメント ファウンデーション | 幹細胞由来移植片からの増殖性細胞の排除 |
| WO2018022946A1 (en) | 2016-07-28 | 2018-02-01 | Alpine Immune Sciences, Inc. | Cd155 variant immunomodulatory proteins and uses thereof |
| US11834490B2 (en) | 2016-07-28 | 2023-12-05 | Alpine Immune Sciences, Inc. | CD112 variant immunomodulatory proteins and uses thereof |
| US11471488B2 (en) | 2016-07-28 | 2022-10-18 | Alpine Immune Sciences, Inc. | CD155 variant immunomodulatory proteins and uses thereof |
| WO2018060833A1 (en) | 2016-09-27 | 2018-04-05 | Novartis Ag | Dosage regimen for alpha-isoform selective phosphatidylinositol 3-kinase inhibitor alpelisib |
| US11154591B2 (en) | 2016-10-14 | 2021-10-26 | The Trustees Of Columbia University In The City Of New York | Methods of treating alcohol abuse disorder |
| AU2017375958A1 (en) | 2016-12-12 | 2019-07-04 | Multivir Inc. | Methods and compositions comprising viral gene therapy and an immune checkpoint inhibitor for treatment and prevention of cancer and infectious diseases |
| CA3045892A1 (en) | 2016-12-12 | 2018-06-21 | Salk Institute For Biological Studies | Tumor-targeting synthetic adenoviruses and uses thereof |
| CN110809581A (zh) | 2017-03-16 | 2020-02-18 | 高山免疫科学股份有限公司 | Pd-l2变体免疫调节蛋白及其用途 |
| RS64870B1 (sr) | 2017-03-16 | 2023-12-29 | Alpine Immune Sciences Inc | Imunomodulatorni proteini varijante pd-l1 i njihove upotrebe |
| SG11201907769XA (en) | 2017-03-16 | 2019-09-27 | Alpine Immune Sciences Inc | Cd80 variant immunomodulatory proteins and uses thereof |
| SG11201908280SA (en) | 2017-03-30 | 2019-10-30 | Univ Queensland | "chimeric molecules and uses thereof" |
| WO2019040994A1 (en) | 2017-09-01 | 2019-03-07 | The Australian National University | IMMUNOREGULATOR MOLECULES AND USES THEREOF |
| EP4219540A3 (de) | 2017-10-10 | 2023-12-06 | Alpine Immune Sciences, Inc. | Ctla-4-variante immunmodulatorische proteine und verwendungen davon |
| TW201925223A (zh) | 2017-10-18 | 2019-07-01 | 美商艾爾潘免疫科學有限公司 | 變異型icos 配位體免疫調節蛋白及相關組合物及方法 |
| WO2019136179A1 (en) | 2018-01-03 | 2019-07-11 | Alpine Immune Sciences, Inc. | Multi-domain immunomodulatory proteins and methods of use thereof |
| AU2019322487B2 (en) | 2018-03-19 | 2024-04-18 | Multivir Inc. | Methods and compositions comprising tumor suppressor gene therapy and CD122/CD132 agonists for the treatment of cancer |
| WO2019241758A1 (en) | 2018-06-15 | 2019-12-19 | Alpine Immune Sciences, Inc. | Pd-1 variant immunomodulatory proteins and uses thereof |
| AU2019345151A1 (en) | 2018-09-19 | 2021-04-29 | Alpine Immune Sciences, Inc. | Methods and uses of variant CD80 fusion proteins and related constructs |
| WO2020113141A2 (en) | 2018-11-30 | 2020-06-04 | Alpine Immune Sciences, Inc. | Cd86 variant immunomodulatory proteins and uses thereof |
| CN110055227A (zh) * | 2019-03-13 | 2019-07-26 | 中国人民解放军第四军医大学 | 用于增生性瘢痕治疗的野生型p53腺病毒及纯化的制备方法 |
| CN114302736A (zh) | 2019-04-17 | 2022-04-08 | 高山免疫科学股份有限公司 | 变体icos配体(icosl)融合蛋白的方法和用途 |
| WO2021113644A1 (en) | 2019-12-05 | 2021-06-10 | Multivir Inc. | Combinations comprising a cd8+ t cell enhancer, an immune checkpoint inhibitor and radiotherapy for targeted and abscopal effects for the treatment of cancer |
| MX2022013998A (es) | 2020-05-08 | 2023-02-16 | Alpine Immune Sciences Inc | Proteinas inmunomoduladoras inhibidoras de april y baff con y sin una proteina inhibidora de celulas t y metodos de uso de las mismas. |
| US20240279310A1 (en) | 2021-05-07 | 2024-08-22 | Alpine Immune Sciences, Inc. | Methods of dosing and treatment with a taci-fc fusion immunomodulatory protein |
| WO2023172883A1 (en) | 2022-03-07 | 2023-09-14 | Alpine Immune Sciences, Inc. | Immunomodulatory proteins of variant cd80 polypeptides, cell therapies thereof and related methods and uses |
| WO2024077018A2 (en) | 2022-10-04 | 2024-04-11 | Alpine Immune Sciences, Inc. | Methods and uses of taci-fc fusion immunomodulatory protein |
Family Cites Families (68)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3950082A (en) * | 1973-01-10 | 1976-04-13 | David Volk | Ophthalmic lens for presbyopia and aphakia |
| US4002439A (en) * | 1973-01-10 | 1977-01-11 | David Volk | Method of forming an ophthalmic lens for presbyopia and aphakia |
| US4050192A (en) * | 1974-12-23 | 1977-09-27 | David Volk | Apparatus for farming ophthalmic lens for presbyopia and aphakia |
| US4149801A (en) * | 1977-02-17 | 1979-04-17 | David Volk | Method and apparatus for measuring aspheric contact lens surfaces |
| US4740463A (en) | 1984-04-13 | 1988-04-26 | Massachusetts Institute Of Technology | Methods and artificial genes for antagonizing the function of an oncogene |
| US4640595A (en) * | 1984-05-02 | 1987-02-03 | David Volk | Aspheric contact lens |
| EP0174608A1 (de) | 1984-09-13 | 1986-03-19 | The Board Of Trustees Of The Leland Stanford Junior University | Beta-Actin-Gen und regulatorische Elemente, deren Herstellung und Verwendung |
| ZA858044B (en) | 1984-11-01 | 1987-05-27 | American Home Prod | Oral vaccines |
| US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| US4710193A (en) * | 1986-08-18 | 1987-12-01 | David Volk | Accommodating intraocular lens and lens series and method of lens selection |
| US5055400A (en) | 1986-11-26 | 1991-10-08 | University Of Guelph | Leukotoxin gene of pasteurella haemolytica |
| US5166320A (en) | 1987-04-22 | 1992-11-24 | University Of Connecticut | Carrier system and method for the introduction of genes into mammalian cells |
| US4980289A (en) | 1987-04-27 | 1990-12-25 | Wisconsin Alumni Research Foundation | Promoter deficient retroviral vector |
| US5532220A (en) | 1987-08-31 | 1996-07-02 | The Regents Of The University Of California | Genetic mechanisms of tumor suppression |
| US5763209A (en) * | 1988-09-26 | 1998-06-09 | Arch Development Corporation | Methods and materials relating to the functional domains of DNA binding proteins |
| AU629554B2 (en) | 1988-06-24 | 1992-10-08 | Juridical Foundation The Chemo-Sero-Therapeutic Research Institute | Exogenous gene expression vector containing chick beta-actin gene promoter |
| AU638954B2 (en) | 1988-10-31 | 1993-07-15 | Regents Of The University Of California, The | Products and methods for controlling the suppression of the neoplastic phenotype |
| WO1990010448A2 (en) | 1989-03-07 | 1990-09-20 | Genentech, Inc. | Covalent conjugates of lipid and oligonucleotide |
| US6677312B1 (en) | 1989-03-29 | 2004-01-13 | The Johns Hopkins University | Methods for restoring wild-type p53 gene function |
| DE69032864T3 (de) | 1989-03-29 | 2013-01-31 | The Johns Hopkins University | Nachweis des Ausfalls des Wildtyps des p53-Gens |
| US5362623A (en) | 1991-06-14 | 1994-11-08 | The John Hopkins University | Sequence specific DNA binding by p53 |
| US6800617B1 (en) | 1989-03-29 | 2004-10-05 | The Johns Hopkins University | Methods for restoring wild-type p53 gene function |
| US5527676A (en) | 1989-03-29 | 1996-06-18 | The Johns Hopkins University | Detection of loss of the wild-type P53 gene and kits therefor |
| US5328470A (en) | 1989-03-31 | 1994-07-12 | The Regents Of The University Of Michigan | Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor |
| US5585362A (en) | 1989-08-22 | 1996-12-17 | The Regents Of The University Of Michigan | Adenovirus vectors for gene therapy |
| SE464777B (sv) | 1989-10-03 | 1991-06-10 | Be Ge Ind Ab | Progressiv luftfjaeder |
| US5200773A (en) * | 1989-10-27 | 1993-04-06 | Volk Donald A | Diagnostic indirect ophthalmoscopy contact lens system |
| US5046836A (en) * | 1989-10-27 | 1991-09-10 | Volk Donald A | Diagnostic indirect ophthmalmoscopy contact lens system |
| IT1238231B (it) | 1989-12-18 | 1993-07-12 | Consiglio Nazionale Ricerche | Impiego di immunomodulanti come agenti sinergici di chemioterapici nella terapia dei tumori |
| IE911115A1 (en) | 1990-04-10 | 1991-10-23 | Canji Inc | Gene therapy for cell proliferative diseases |
| NO312681B1 (no) | 1990-08-24 | 2002-06-17 | Univ California | Fremgangsmåte for fremstilling av en farmasöytisk blanding med suppresiv virkning/aktivitet |
| US6410010B1 (en) | 1992-10-13 | 2002-06-25 | Board Of Regents, The University Of Texas System | Recombinant P53 adenovirus compositions |
| US5747469A (en) * | 1991-03-06 | 1998-05-05 | Board Of Regents, The University Of Texas System | Methods and compositions comprising DNA damaging agents and p53 |
| DE69233013T2 (de) | 1991-08-20 | 2004-03-04 | The Government Of The United States Of America As Represented By The Secretary Of National Institute Of Health, Office Of Technology Transfer | Adenovirus vermittelter gentransfer in den gastrointestinaltrakt |
| US5255025A (en) * | 1991-10-15 | 1993-10-19 | Volk Donald A | Measurement apparatus for indirect ophthalmoscopy |
| US5252479A (en) | 1991-11-08 | 1993-10-12 | Research Corporation Technologies, Inc. | Safe vector for gene therapy |
| FR2688514A1 (fr) * | 1992-03-16 | 1993-09-17 | Centre Nat Rech Scient | Adenovirus recombinants defectifs exprimant des cytokines et medicaments antitumoraux les contenant. |
| US5428011A (en) | 1992-06-16 | 1995-06-27 | Procyon Biopharma, Inc. | Pharmaceutical preparations for inhibiting tumours associated with prostate adenocarcinoma |
| US6348352B1 (en) | 1992-09-18 | 2002-02-19 | Canji, Inc. | Methods for selectively transducing pathologic mammalian cells using a tumor suppressor gene |
| WO1994008026A1 (en) | 1992-09-25 | 1994-04-14 | Rhone-Poulenc Rorer S.A. | Adenovirus vectors for the transfer of foreign genes into cells of the central nervous system, particularly in brain |
| US5347326A (en) * | 1992-10-05 | 1994-09-13 | Volk Donald A | Diagnostic or therapeutic contact lens |
| GB9223084D0 (en) * | 1992-11-04 | 1992-12-16 | Imp Cancer Res Tech | Compounds to target cells |
| US5430506A (en) * | 1992-11-06 | 1995-07-04 | Volk; Donald A. | Indirect ophthalmoscopy lens for use with slit lamp biomicroscope |
| DK0931830T3 (da) | 1993-02-16 | 2001-06-11 | Onyx Pharma Inc | Cytopatiske vira til terapi og profylakse af neoplasi |
| US5496731A (en) | 1993-03-25 | 1996-03-05 | Xu; Hong-Ji | Broad-spectrum tumor suppressor genes, gene products and methods for tumor suppressor gene therapy |
| FR2704234B1 (fr) * | 1993-04-22 | 1995-07-21 | Centre Nat Rech Scient | Virus recombinants, preparation et utilisation en therapie genique. |
| FR2705361B1 (fr) | 1993-05-18 | 1995-08-04 | Centre Nat Rech Scient | Vecteurs viraux et utilisation en thérapie génique. |
| RU2219241C2 (ru) * | 1993-07-13 | 2003-12-20 | Рон-Пуленк Роре С.А. | Дефектный рекомбинантный аденовирусный вектор (варианты) |
| WO1995011301A1 (en) | 1993-10-19 | 1995-04-27 | The Regents Of The University Of Michigan | P53-mediated apoptosis |
| PT797676E (pt) | 1993-10-25 | 2006-05-31 | Canji Inc | Vector adenoviral recombinante e metodos de utilizacao |
| US6210939B1 (en) * | 1993-10-25 | 2001-04-03 | Canji, Inc. | Recombinant adenoviral vector and methods of use |
| TW442569B (en) | 1993-10-25 | 2001-06-23 | Canji Inc | Recombinant adenoviral vector |
| US5440458A (en) * | 1993-11-02 | 1995-08-08 | Volk; Donald A. | Illuminated lens case |
| US5479222A (en) * | 1993-11-15 | 1995-12-26 | Volk; Donald A. | Indirect ophthalmoscopy lens system and adapter lenses |
| FR2712602B1 (fr) | 1993-11-18 | 1996-02-09 | Centre Nat Rech Scient | Virus recombinants, préparation et utilisation en thérapie génique. |
| FR2712603B1 (fr) | 1993-11-18 | 1996-02-09 | Centre Nat Rech Scient | Virus recombinants, préparation et utilisation en thérapie génique. |
| FR2716893B1 (fr) | 1994-03-03 | 1996-04-12 | Rhone Poulenc Rorer Sa | Virus recombinants, leur préparation et leur utilisation thérapeutique. |
| US5436680A (en) * | 1994-04-20 | 1995-07-25 | Volk; Donald A. | Indirect ophthalmoscopy lens providing apparent image curvature |
| EP0758382A1 (de) | 1994-04-29 | 1997-02-19 | Sidney Kimmel Cancer Center | Erhoehung der empfindlichkeit von tumorzellen fuer therapie |
| US5526074A (en) * | 1994-10-31 | 1996-06-11 | Volk; Donald A. | Full field reinverting indirect contact ophthalmoscope |
| US5523810C1 (en) * | 1995-06-05 | 2001-04-17 | Volk Optical Inc | Indirect ophthalmoscopy contact lens device with compound contact lens element |
| EP0761613B1 (de) * | 1995-09-07 | 2001-10-24 | Ford Motor Company | Verfahren zum Erhitzen und Formen von Glastafeln |
| US5805269A (en) * | 1996-08-27 | 1998-09-08 | Volk Optical, Inc. | High magnification indirect ophthalmoscopy lens device |
| US5757464A (en) * | 1996-08-29 | 1998-05-26 | Volk Optical, Inc. | Indirect ophthalmoscopy contact lens device with compound contact lens element |
| EP1017308B1 (de) * | 1996-10-24 | 2003-06-04 | Volk Optical, Inc. | Beobachtungsvorrichtung für die augenheilkunde |
| US5986801A (en) * | 1996-11-08 | 1999-11-16 | Volk; Donald A. | Image reinverter for stereo microscope |
| US5857475A (en) * | 1997-03-03 | 1999-01-12 | Volk Optical, Inc. | Optical component cleaning apparatus |
| US5963301A (en) * | 1997-10-22 | 1999-10-05 | Volk Optical, Inc. | Lense arrangement for vitreoretinal surgery |
-
1993
- 1993-10-29 US US08/145,826 patent/US6410010B1/en not_active Expired - Lifetime
-
1994
- 1994-04-07 US US08/224,232 patent/US6143290A/en not_active Expired - Lifetime
- 1994-10-28 SK SK509-96A patent/SK50996A3/sk unknown
- 1994-10-28 EP EP94932099A patent/EP0725791B1/de not_active Expired - Lifetime
- 1994-10-28 KR KR1020057005235A patent/KR100812631B1/ko not_active IP Right Cessation
- 1994-10-28 UA UA96041651A patent/UA73265C2/uk unknown
- 1994-10-28 PL PL94314311A patent/PL186151B1/pl not_active IP Right Cessation
- 1994-10-28 NZ NZ275356A patent/NZ275356A/en not_active IP Right Cessation
- 1994-10-28 BR BR9408179A patent/BR9408179A/pt not_active Application Discontinuation
- 1994-10-28 AU AU80949/94A patent/AU698437B2/en not_active Ceased
- 1994-10-28 CN CN94194354A patent/CN1079833C/zh not_active Expired - Lifetime
- 1994-10-28 AT AT94932099T patent/ATE525387T1/de not_active IP Right Cessation
- 1994-10-28 HU HU9601084A patent/HU222981B1/hu not_active IP Right Cessation
- 1994-10-28 KR KR1019960702193A patent/KR960705930A/ko not_active Application Discontinuation
- 1994-10-28 CZ CZ19961225A patent/CZ288790B6/cs not_active IP Right Cessation
- 1994-10-28 CA CA002174556A patent/CA2174556C/en not_active Expired - Fee Related
- 1994-10-28 WO PCT/US1994/012401 patent/WO1995012660A2/en active Application Filing
- 1994-10-28 RU RU96110223/13A patent/RU2222600C2/ru not_active IP Right Cessation
- 1994-10-28 JP JP7513310A patent/JPH10503361A/ja active Pending
-
1995
- 1995-06-02 US US08/459,713 patent/US6740320B1/en not_active Expired - Lifetime
-
1996
- 1996-04-02 US US08/626,678 patent/US6905873B1/en not_active Expired - Fee Related
- 1996-04-26 NO NO961696A patent/NO961696L/no unknown
-
1999
- 1999-10-06 US US09/413,109 patent/US6805858B1/en not_active Expired - Fee Related
-
2000
- 2000-09-21 US US09/668,532 patent/US6511847B1/en not_active Expired - Fee Related
-
2002
- 2002-06-11 US US10/170,240 patent/US7033750B2/en not_active Expired - Fee Related
- 2002-06-25 US US10/180,895 patent/US6830749B2/en not_active Expired - Fee Related
-
2003
- 2003-02-19 JP JP2003041578A patent/JP2003265193A/ja active Pending
-
2005
- 2005-10-14 US US11/251,111 patent/US20070190040A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UA73265C2 (en) | Adenovirus-recombinant carrying the structure of adenovirus vector, a method for the restoration of protein p53 function in tumor cell with deficit of natural p53, a method for the preparation of adenovirus-recombinant | |
| DE69417734T2 (de) | Cytopathische viren zur therapie und prophylaxe der neoplasie | |
| RU2146149C1 (ru) | Способ и композиции, содержащие dna-поражающие агенты и р53 | |
| US5801029A (en) | Cytopathic viruses for therapy and prophylaxis of neoplasia | |
| DE69726759T2 (de) | Cytopatische viren zur therapie und prophylaxe der neoplasie | |
| US6326356B1 (en) | Suppression of neu overexpression using a mini-E1A gene | |
| ES2385347T3 (es) | Virus con potencia lítica mejorada | |
| TWI391486B (zh) | 新穎啟動子及包含其之病毒載體 | |
| KREMSDORF et al. | H. SIRMA, C. GIANNINI, K. POUSSIN, P. PATERLINI |